Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes | Zendy

Benjamin Harris | Zendy; Viet Hong Phan | Zendy; Vidya Perera | Zendy; Anneliese Szyc | Zendy; Peter Galettis | Zendy; Jennifer Martin | Zendy; Euan Walpole | Zendy; Andrew J. McLachlan | Zendy; Stephen Clarke | Zendy; Stephanie E. Reuter | Zendy; Kellie A. Charles | Zendy

Open Access

Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes

Author(s) -

Benjamin Harris,

Viet Hong Phan,

Vidya Perera,

Anneliese Szyc,

Peter Galettis,

Jennifer Martin,

Euan Walpole,

Andrew J. McLachlan,

Stephen Clarke,

Stephanie E. Reuter,

Kellie A. Charles

Publication year - 2020

Publication title -

clinical pharmacokinetics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.549

H-Index - 164

eISSN - 1179-1926

pISSN - 0312-5963

DOI - 10.1007/s40262-020-00870-6

Subject(s) - carboplatin , medicine , dosing , lung cancer , oncology , inflammation , cancer , systemic inflammation , intensive care medicine , chemotherapy , cisplatin

The presence of elevated systemic inflammation in people with advanced non-small cell lung cancer (NSCLC) is associated with significantly shorter survival following carboplatin-based chemotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research